{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:43:10Z","timestamp":1770748990670,"version":"3.50.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["T32HP42019"],"award-info":[{"award-number":["T32HP42019"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["T32HP42019"],"award-info":[{"award-number":["T32HP42019"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00726-3","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:12:27Z","timestamp":1739945547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Promises, Pitfalls, and Progress: Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections"],"prefix":"10.1007","volume":"22","author":[{"given":"Christopher J","family":"Kaperak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-4465","authenticated-orcid":false,"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"726_CR1","volume-title":"Progress report on HIV, viral hepatitis and sexually transmitted infections 2019: accountability for the global health sector strategies, 2016\u20132021. No. WHO\/CDS\/HIV\/19.7","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019: accountability for the global health sector strategies, 2016\u20132021. No. WHO\/CDS\/HIV\/19.7. World Health Organization; 2019."},{"key":"726_CR2","volume-title":"Sexually transmitted infections Surveillance 2023","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted infections Surveillance 2023. Atlanta: US Department of Health and Human Services; 2024."},{"issue":"46","key":"726_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.15585\/mmwr.mm7246e1","volume":"72","author":"R McDonald","year":"2023","unstructured":"McDonald R, O\u2019Callaghan K, Torrone E, et al. Vital signs: missed opportunities for preventing congenital syphilis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(46):1269\u201374. https:\/\/doi.org\/10.15585\/mmwr.mm7246e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"726_CR4","doi-asserted-by":"publisher","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1\u2013187. https:\/\/doi.org\/10.15585\/mmwr.rr7004a1.\u00a0","DOI":"10.15585\/mmwr.rr7004a1"},{"issue":"RR\u20132","key":"726_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7302a1","volume":"73","author":"LH Bachmann","year":"2024","unstructured":"Bachmann LH, Barbee LA, Chan P, et al. CDC Clinical guidelines on the use of doxycycline postexposure prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recomm Rep. 2024;73(RR\u20132):1\u20138. https:\/\/doi.org\/10.15585\/mmwr.rr7302a1.","journal-title":"MMWR Recomm Rep"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"ciae062","DOI":"10.1093\/cid\/ciae062","volume":"9","author":"A Hazra","year":"2024","unstructured":"Hazra A, McNulty MC, Pyra M et al. Filling in the gaps: updates on doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis 2024 Feb 9:ciae062. https:\/\/doi.org\/10.1093\/cid\/ciae062","journal-title":"Clin Infect Dis"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"18","author":"JM Molina","year":"2018","unstructured":"Molina JM, Charreau I, Chidiac C, ANRS IPERGAY Study Group, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18:308\u201317. https:\/\/doi.org\/10.1016\/S1473-3099(17)30725-9.","journal-title":"Lancet Infect Dis"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388:1296\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa2211934.","journal-title":"N Engl J Med"},{"issue":"10","key":"726_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","volume":"24","author":"JM Molina","year":"2024","unstructured":"Molina JM, Bercot B, Assoumou L, ANRS 174 DOXYVAC Study Group, et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2\u2008\u00d7\u20082 factorial design. Lancet Infect Dis. 2024;24(10):1093\u2013104. https:\/\/doi.org\/10.1016\/S1473-3099(24)00236-6.","journal-title":"Lancet Infect Dis"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","volume":"389","author":"J Stewart","year":"2023","unstructured":"Stewart J, Oware K, Donnell D, dPEP Kenya Study Team, et al. Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med. 2023;389:2331\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2304007.","journal-title":"N Engl J Med"},{"key":"726_CR11","unstructured":"University of Zurich. Doxycycline PEP and 4CMenB as a comprehensive prevention strategy in MSM and TGW at high risk for bacterial STIs within the Swiss HIV cohort study. clinicaltrials.gov; 2024. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06242730"},{"key":"726_CR12","unstructured":"World Health Organization. Periodic presumptive treatment for sexually transmitted infections: experience from the field and recommendations for research. Traitement pr\u00e9somptif p\u00e9riodique des infections sexuellement transmissibles : exp\u00e9rience sur le terrain et recommandations relatives \u00e0 la recherche. Published online 2008. Accessed November 12, 2024. https:\/\/iris.who.int\/handle\/10665\/43950"},{"key":"726_CR13","unstructured":"ATN 173. The adolescent medicine trials network for HIV interventions. September 13, 2024. Accessed November 12, 2024. https:\/\/www.atnconnect.org\/atn-173\/"},{"key":"726_CR14","unstructured":"ATN 166. The adolescent medicine trials network for HIV interventions. August 23, 2023. Accessed November 12, 2024. https:\/\/www.atnconnect.org\/atn-166\/"},{"issue":"2","key":"726_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/OLQ.0000000000000216","volume":"42","author":"RK Bolan","year":"2015","unstructured":"Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to Reduce Incident Syphilis among HIV-Infected men who have sex with men who continue to engage in high risk sex: a Randomized, Controlled Pilot Study. Sex Transm Dis. 2015;42(2):98. https:\/\/doi.org\/10.1097\/OLQ.0000000000000216.","journal-title":"Sex Transm Dis"},{"key":"726_CR16","unstructured":"Grennan T et al. Daily doxycycline in MSM on PrEP for prevention of sexually transmitted infections [Abstract 709]. In: Conference on Retroviruses and Opportunistic Infections (CROI). Virtual. 2021."},{"key":"726_CR17","doi-asserted-by":"publisher","unstructured":"Grennan T, Mohammed S, Edward J, Tattersall T, Gupta AK, Seto J, Dennehy M, Romney MG, Zhang W, Li J, Trigg J, Lima VD, Juwono S, Wong J, Zhang G, Montaner JSG, Hull MW. A pilot, randomized controlled trial of Dual Daily HIV and sexually transmitted infection pre-exposure prophylaxis using tenofovir disoproxil fumarate\/emtricitabine and doxycycline in gay, bisexual and other men who have sex with men and transgender women: The DuDHS Study. Clin Infect Dis. 2025. p. ciaf043. https:\/\/doi.org\/10.1093\/cid\/ciaf043.","DOI":"10.1093\/cid\/ciaf043"},{"key":"726_CR18","unstructured":"Abe S, et al. Doxycycline PrEP prevents STIs without affecting vaginal bacterial flora in female sex workers [Abstract OAC0803]. In: 2024 International AIDS Conference. Munich; 2024."},{"key":"726_CR19","unstructured":"Kirby Institute. Impact of the daily doxycycline Pre-Exposure Prophylaxis (PrEP) on the incidence of syphilis, gonorrhoea and chlamydia. clinicaltrials.gov. 2023. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03709459"},{"key":"726_CR20","unstructured":"Baeten J. Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya. clinicaltrials.gov; 2024. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06582966"},{"key":"726_CR21","unstructured":"Grennan JT. A randomized trial of doxycycline chemoprophylaxis for the prevention of sexually transmitted infections in gay, bisexual and other men who have sex with men (gbMSM). clinicaltrials.gov; 2024. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04762134"},{"key":"726_CR22","unstructured":"Kwan TH. Superiority of on-demand pre-exposure prophylaxis versus post-exposure prophylaxis on using doxycycline for preventing sexually transmitted infections in men who have sex with men. clinicaltrials.gov; 2023. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06188442"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"105037","DOI":"10.1016\/j.ebiom.2024.105037","volume":"101","author":"RE Haaland","year":"2024","unstructured":"Haaland RE, Fountain J, Edwards TE, et al. Pharmacokinetics of single dose doxycycline in the rectum, vagina, and urethra: implications for prevention of bacterial sexually transmitted infections. eBioMedicine. 2024;101:105037. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105037.","journal-title":"eBioMedicine"},{"key":"726_CR24","unstructured":"Kelley C. Doxy-PEP: Dose-ranging study of persons receiving doxycycline. clinicaltrials.gov; 2024. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05853120"},{"key":"726_CR25","unstructured":"Kelley C. Daily Doxy: Study of persons receiving daily doxycycline to inform sexually transmitted infection prophylaxis regimens. clinicaltrials.gov; 2024. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06545656"},{"key":"726_CR26","unstructured":"University of California, San Francisco. Randomized directly observed therapy study to interpret clinical trials of Doxy-PEP. clinicaltrials.gov; 2024. Accessed November 12. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06414408"},{"key":"726_CR27","unstructured":"Assistance Publique - H\u00f4pitaux de Paris. Caract\u00e9risation de La Pharmacocin\u00e9tique D\u2019Une Dose Unique de 200 Mg de Doxycycline En Prophylaxie Post-Exposition (PEP) Des Infections Sexuellement Transmissibles Dans Diff\u00e9rents Compartiments Biologiques. clinicaltrials.gov;2024. Accessed November 12, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06007534."},{"issue":"2","key":"726_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/jcph.2358","volume":"64","author":"P Waitayangkoon","year":"2024","unstructured":"Waitayangkoon P, Moon SJ, Tirupur Ponnusamy JJ, Zeng L, Driban J, McAlindon T. Long-term safety profiles of Macrolides and tetracyclines: a systematic review and Meta-analysis. J Clin Pharmacol. 2024;64(2):164\u201377. https:\/\/doi.org\/10.1002\/jcph.2358.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"726_CR29","first-page":"19","volume":"8","author":"JQD Rosso","year":"2015","unstructured":"Rosso JQD. Oral doxycycline in the management of Acne Vulgaris: current perspectives on clinical use and recent findings with a new double-scored small Tablet Formulation. J Clin Aesthetic Dermatol. 2015;8(5):19.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"11","key":"726_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/OLQ.0000000000001865","volume":"50","author":"PA Chan","year":"2023","unstructured":"Chan PA, et al. Safety of longer-term doxycycline use: a systematic review and Meta-analysis with implications for bacterial sexually transmitted infection Chemoprophylaxis. Sex Transm Dis. 2023;50(11):701\u201312.","journal-title":"Sex Transm Dis"},{"key":"726_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03274-2","author":"VT Chu","year":"2024","unstructured":"Chu VT, Glascock A, Donnell D, et al. Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03274-2.","journal-title":"Nat Med"},{"issue":"1","key":"726_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12879-024-09275-3","volume":"24","author":"T Vanbaelen","year":"2024","unstructured":"Vanbaelen T, Manoharan-Basil SS, Kenyon C. 45 years of tetracycline post exposure prophylaxis for STIs and the risk of tetracycline resistance: a systematic review and meta-analysis. BMC Infect Dis. 2024;24(1):376. https:\/\/doi.org\/10.1186\/s12879-024-09275-3.","journal-title":"BMC Infect Dis"},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"1208014","DOI":"10.3389\/fmicb.2023.1208014","volume":"14","author":"C Kenyon","year":"2023","unstructured":"Kenyon C, Gestels Z, Vanbaelen T, Abdellati S, Van Den Bossche D, De Baetselier I, Xavier BB, Manoharan-Basil SS. Doxycycline PEP can induce doxycycline resistance in Klebsiella pneumoniae in a Galleria mellonella model of PEP. Front Microbiol. 2023;14:1208014. https:\/\/doi.org\/10.3389\/fmicb.2023.1208014. PMID: 37711686; PMCID: PMC10498386.","journal-title":"Front Microbiol"},{"issue":"5","key":"726_CR34","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/cid\/ciad279.36993406","volume":"77","author":"TD Mortimer","year":"2023","unstructured":"Mortimer TD, Grad YH. A genomic perspective on the near-term impact of doxycycline post-exposure prophylaxis on Neisseria gonorrhoeae antimicrobial resistance. Clin Infect Dis. 2023;77(5):788\u201391. https:\/\/doi.org\/10.1093\/cid\/ciad279.36993406.","journal-title":"Clin Infect Dis"},{"key":"726_CR35","doi-asserted-by":"publisher","unstructured":"Kenyon C. The importance of not downplaying the risks that doxycycline postexposure prophylaxis will select for antimicrobial resistance. Clin Infect Dis. 2024;ciae139. https:\/\/doi.org\/10.1093\/cid\/ciae139.","DOI":"10.1093\/cid\/ciae139"},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"ciae152","DOI":"10.1093\/cid\/ciae152","volume":"19","author":"A Hazra","year":"2024","unstructured":"Hazra A, Celum C, Luetkemeyer AF, Molina JM, Klausner JD. Risk of antimicrobial resistance with doxy-PEP is real, as is the need for its well-informed implementation. Clin Infect Dis 2024 Mar 19:ciae152. https:\/\/doi.org\/10.1093\/cid\/ciae152","journal-title":"Clin Infect Dis"},{"key":"726_CR37","unstructured":"Luetkemeyer A et al. Sustained reduction of bacterial STIs during the DoxyPEP study open-label extension. Conference on retroviruses and opportunistic infections, Denver, abstract 125, 2024."},{"issue":"4","key":"726_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/apc.2023.0289","volume":"38","author":"RJ Fredericksen","year":"2024","unstructured":"Fredericksen RJ, Perkins R, Brown CE, Cannon C, Lopez C, Cohee A, Dombrowski JC, Cohen S, Malinski C, Powell M, Luetkemeyer AF, Celum C, Christopoulos K. Doxycycline as Postsexual exposure Prophylaxis: use, acceptability, and Associated sexual health behaviors among a multi-site sample of clinical trial participants. AIDS Patient Care STDS. 2024;38(4):155\u201367. https:\/\/doi.org\/10.1089\/apc.2023.0289.","journal-title":"AIDS Patient Care STDS"},{"issue":"6","key":"726_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/sextrans-2024-056152","volume":"100","author":"PA Chan","year":"2024","unstructured":"Chan PA, Malyuta Y, Parent H, Tao J, Erbe M, Salhaney P, Maynard M, DeWitt W, Reisopoulos A, Nunn A. Early adopters of doxycycline as post-exposure prophylaxis to prevent bacterial sexually transmitted infections in a real-world clinical setting. Sex Transm Infect. 2024;100(6):339\u201342. https:\/\/doi.org\/10.1136\/sextrans-2024-056152.","journal-title":"Sex Transm Infect"},{"key":"726_CR40","unstructured":"Lopes da Rosa-Spiegler J et al. Use of doxyPEP by men who have sex with men in Atlanta [Abstract O5.1]. In: STI Prevention 2024. Atlanta; 2024."},{"key":"726_CR41","unstructured":"Gilliams E et al. Early implementation of doxycycline post-exposure prophylaxis at public sexual health clinics in Baltimore, MD [Abstract O5.2]. In: STI Prevention 2024. Atlanta; 2024."},{"key":"726_CR42","unstructured":"Carnevale C et al. Implementation of doxy-PEP in a diverse sexual health program in northern Manhattan [Abstract O5.3]. In: STI Prevention 2024. Atlanta; 2024."},{"key":"726_CR43","doi-asserted-by":"crossref","unstructured":"Chan PA et al. Early adopters of doxycycline as post-exposure prophylaxis to prevent bacterial STIs in a real-world clinical setting [Abstract O5.4]. In: STI Prevention 2024. Atlanta; 2024.","DOI":"10.1136\/sextrans-2024-056152"},{"key":"726_CR44","doi-asserted-by":"publisher","unstructured":"Sankaran M, Glidden DV, Kohn RP, Nguyen TQ, Bacon O, Buchbinder SP, Gandhi M, Havlir DV, Liebi C, Luetkemeyer AF, Nguyen JQ, Roman J, Scott H, Torres TS, Cohen SE. Doxycycline postexposure prophylaxis and sexually transmitted infection trends. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7178.","DOI":"10.1001\/jamainternmed.2024.7178"},{"issue":"11","key":"726_CR45","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/OLQ.0000000000001996","volume":"51","author":"A Liu","year":"2024","unstructured":"Liu A, Hao J, Pickering TA, Klausner JD. Trends in sexually transmitted infections Associated with the doxycycline postexposure Prophylaxis guidelines in San Francisco. Sex Transm Dis. 2024;51(11):e46\u20138. https:\/\/doi.org\/10.1097\/OLQ.0000000000001996.","journal-title":"Sex Transm Dis"},{"issue":"12","key":"726_CR46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/OLQ.0000000000002061","volume":"51","author":"MW Traeger","year":"2024","unstructured":"Traeger MW, Krakower DS, Mayer KH, Jenness SM, Marcus JL. Use of doxycycline and other antibiotics as bacterial sexually transmitted infection Prophylaxis in a US sample of primarily Gay and Bisexual men. Sex Transm Dis. 2024;51(12):763\u201371. https:\/\/doi.org\/10.1097\/OLQ.0000000000002061.","journal-title":"Sex Transm Dis"},{"key":"726_CR47","unstructured":"Stoner B. $4.8 Million Minority HIV\/AIDS Fund Investment Supports CDC Awards for Doxy PEP Implementation and HIV\/Syphilis Point-of-Care Testing HIV\/AIDS Fund (MHAF). HIV.gov. October 24th, 2024. https:\/\/www.hiv.gov\/blog\/4-8-million-minority-hiv-aids-fund-investment-supports-cdc-awards-for-doxy-pep-implementation-and-hiv-syphilis-point-of-care-testing. Accessed November 4th, 2024."},{"issue":"4","key":"726_CR48","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/OLQ.0000000000001130","volume":"47","author":"L Fusca","year":"2020","unstructured":"Fusca L, Hull M, Ross P, Grennan T, Burchell AN, Bayoumi AM, Tan DHS. High interest in Syphilis Pre-exposure and Post-exposure Prophylaxis among Gay, bisexual and other men who have sex with men in Vancouver and Toronto. Sex Transm Dis. 2020;47(4):224\u201331. https:\/\/doi.org\/10.1097\/OLQ.0000000000001130.","journal-title":"Sex Transm Dis"},{"issue":"7","key":"726_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/OLQ.0b013e31820e64fd","volume":"38","author":"DP Wilson","year":"2011","unstructured":"Wilson DP, Prestage GP, Gray RT, Hoare A, McCann P, Down I, Guy RJ, Drummond F, Klausner JD, Donovan B, Kaldor JM. Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis. 2011;38(7):573\u20139. https:\/\/doi.org\/10.1097\/OLQ.0b013e31820e64fd.","journal-title":"Sex Transm Dis"},{"key":"726_CR50","doi-asserted-by":"publisher","unstructured":"Sergio VB, Ruben M, Luis V. A practice already in use: a snapshot survey on the use of doxycycline as a preventive strategy (Doxy-PEP and Doxy-PrEP) in the GBMSM population in Spain. Infect 2024 Jul 25. https:\/\/doi.org\/10.1007\/s15010-024-02320-y","DOI":"10.1007\/s15010-024-02320-y"},{"issue":"6","key":"726_CR51","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s15010-023-02086-9","volume":"51","author":"D Hornuss","year":"2023","unstructured":"Hornuss D, Math\u00e9 P, Usadel S, Zimmermann S, M\u00fcller M, Rieg S. Already current practice? A snapshot survey on doxycycline use for prevention of sexually transmitted infections in parts of the German MSM community. Infection. 2023;51(6):1831\u20134. https:\/\/doi.org\/10.1007\/s15010-023-02086-9.","journal-title":"Infection"},{"key":"726_CR52","doi-asserted-by":"publisher","unstructured":"Wagner L, Boesecke C, Baumgarten A, Scholten S, Schellberg S, Hoffmann C, Audebert F, Noe S, Erber J, Lee M, Triebelhorn J, Schneider J, Spinner CD, Voit F. Is doxycycline post-exposure prophylaxis being utilised in Germany? Insights from an online survey among German men who have sex with men. Infection. 2024 Jul;23. https:\/\/doi.org\/10.1007\/s15010-024-02321-x.","DOI":"10.1007\/s15010-024-02321-x"},{"key":"726_CR53","unstructured":"Mayer KH, et al. Rapid doxycycline post-exposure prophylaxis (doxyPEP) uptake and subsequent bacterial sexually transmitted infections (BSTI) in a Boston community health center (BCHC) [Abstract O5.5]. In: STI Prevention 2024. Atlanta; 2024."},{"issue":"11","key":"726_CR54","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/jama.2024.0464","volume":"331","author":"J Marrazzo","year":"2024","unstructured":"Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, Kiragu M, Reza-Paul S, Myers J, Bekker LG, Yang J, Carter C, de Boer M, Das M, Baeten JM, Celum C. HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among cisgender women. JAMA. 2024;331(11):930\u20137. https:\/\/doi.org\/10.1001\/jama.2024.0464.","journal-title":"JAMA"},{"key":"726_CR55","unstructured":"Hazra A, et al. Use of doxycycline for STI post-exposure prophylaxis in people assigned female at birth in the United States [Abstract O17.4]. In: STI Prevention 2024. Atlanta; 2024."}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00726-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00726-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00726-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:03:53Z","timestamp":1769609033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00726-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00726-3","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"1 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent Statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16"}}